Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor

Medical Oncology

Volumn 26, Issue 4, 2009, Pages 480-490

  Linderholm, B ^a,b   Bergqvist, J ^a   Hellborg, H ^a   Johansson, U ^a   Linderholm, M ^b   Von Schoultz, E ^a   Elmberger, G ^a   Skoog, L ^a   Bergh, J ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adjuvant endocrine therapy; Angiogenesis; ER PgR status; HER2; Survival; VEGF

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; VASCULOTROPIN;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GENE OVEREXPRESSION; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GOSERELIN; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAMOXIFEN; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70949085372     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-008-9157-9     Document Type: Article

References (32)

1. Early Breast Cancer Trialists, Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet. 1992;399:1-15.
2. M Dowsett 2001 Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer Endocr Relat Cancer 8 191 4 10.1677/erc.0.0080191 1:CAS:528:DC%2BD3MXotlCqsLg%3D 11566610 (Pubitemid 32947641)
3. Honig SF. Treatment of metastatic disease: hormonal therapy and chemotherapy. In: Harris JR, Lippman ME, Morrow M, Hellman S, editors. Diseases of the breast. Philadelphia, PA: Lippincott-Raven; 1996. p. 669-734.
4. A Goldhirsh M Colleoni R Gelber 2002 Endocrin therapy in breast cancer Ann Oncol 13 Suppl 4 61 8
5. R Schiff S Massarweh J Shou K Osborn 2003 Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response Clin Cancer Res 9 447 54 Suppl
6. Johnston SRD, Andersson E, Dowsett M, Howell A. Hormonal resistance in breast cancer. In: Oettel M, Schillinger E, editors. Handbook of experimental pharmacology: estrogens and antiestrogens II. Berlin: Springer-Verlag; 1999. p. 205-11.
7. SRD Johnston G Saccanti-Jotti IE Smith J Newby M Dowsett 1995 Change in oestrogen receptor expression and function in tamoxifen-resistant breast cancer Endocr Relat Cancer 2 105 10 10.1677/erc.0.0020105 1:CAS:528:DyaK2MXns1aks7w%3D
8. SM Aronica BS Katzenellenbogen 1993 Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclin adenosine monophosphate, and insulin-like growth factor-I Mol Endocrinol 7 743 52 10.1210/me.7.6.743 1:CAS:528:DyaK2cXitlOmuw%3D%3D 7689695 (Pubitemid 23207377)
9. RJ Pietras J Arboleda DM Reese N Wongvipat MD Pegram MG Parker MX Sliwkowski DJ Slamon 1995 HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells Oncogene 10 2435 46 1:CAS:528:DyaK2MXmsFCgtr4%3D 7784095
10. G Bunone PA Briand RJ Miksicek D Picard 1996 Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation EMBO J 15 2174 83 1:CAS:528:DyaK28XjtFyjtrs%3D 8641283
11. S De Placido C Carlomagno M De Laurentis AR Bianco 1998 c-erbB-2 expression predicts tamoxifen efficacy in breast cancer patients Breast Cancer Res Treat 52 55 64 10.1023/A:1006159001039 10066072 (Pubitemid 29056085)
12. B Linderholm K Grankvist N Wilking M Johansson B Tavelin R Henriksson 2000 Correlation of Vascular Endothelial Growth Factor (VEGF) and survival, metastasis sites and responsiveness to adjuvant systemic treatment in primary node-positive breast carcinoma J Clin Oncol 18 1423 31 1:CAS:528: DC%2BD3cXivVeisro%3D 10735889
13. B Linderholm J Andersson B Lindh B Tavelin M Erlanson L Beckman K Grankvist R Henriksson 2004 Overexpression of c-erbB-2 is related with higher expression of vascular endothelial growth factor (VEGF) and of prognostic value in primary node-positive breast cancer following adjuvant systemic therapy Eur J Cancer 40 1 33 42 10.1016/S0959-8049(03)00673-7 1:CAS:528:DC%2BD3sXpvVWhtrk%3D 14687787 (Pubitemid 37542315)
14. Rutqvist LE. Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer: a randomised trial by the Cancer Research Campaign (C.R.C) Breast Cancer Trial Group, the Stockholm Breast Cancer Study Group, the South-East Sweden Breast Cancer Group & the Gruppo Interdisciplinare Valutazione Interventi di Oncologia (G.I.V.I.O.). Proc Am Soc Clin Oncol. 1999;18:67a, (abstr 251).
15. D Coradini E Biganzoli C Pellizzaro C Veneroni S Oriana F Ambrogini, et al. 2003 Vascular endothelial growth factor in node-positive breast cancer patients treated with adjuvant tamoxifen Br J Cancer 89 268 70 10.1038/sj.bjc.6601060 1:CAS:528:DC%2BD3sXlsVakt7g%3D 12865915 (Pubitemid 36976314)
16. JK Ruhola EM Valve MJ Karkkainen V Joukov K Alitalo PL Harkonen 1999 Vascular endothelial growth factors are differentially expressed by steroid hormones and antiestrogens in breast cancer cells Mol Cell Endocrinol 149 29 40 10.1016/S0303-7207(99)00003-9 (Pubitemid 29236221)
17. SM Hyder L Murthy GM Stancel 1998 Progestin regulation of vascular endothelial growth factor in human breast cancer cells Cancer Res 58 392 5 1:CAS:528:DyaK1cXnsFejsA%3D%3D 9458078
18. SM Hyder GM Stancel 2000 Regulation of vascular endothelial growth factor by sex steroids Histol Histopathol 15 325 34 1:CAS:528:DC%2BD3cXhs1yiu74%3D 10668221
19. SM Hyder Z Nawas C Chiapetta GM Stancel 2000 Identification of functional estrogen receptor response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor Cancer Res 60 3183 90 1:CAS:528:DC%2BD3cXktlyktbc%3D 10866309
20. SM Hyder C Chiapetta L Murthy GM Stancel 1997 Selective inhibition of estrogen-regulated gene expression in vivo by the pure antiestrogen ICI 182, 780 Cancer Res 57 2547 9 1:CAS:528:DyaK2sXkt12ltLw%3D 9205050
21. T Miralem R Steinberg D Price H Avraham 2001 VEGF(165) requires extra-cellular matrix components to induce mitogenic effects and migratory response in breast cancer cells Oncogene 20 5511 24 10.1038/sj.onc.1204753 1:CAS:528:DC%2BD3MXntFWjsbg%3D 11571649 (Pubitemid 32889488)
22. RT-P Poon S-T Fan J Wong 2001 Clinical implications of circulating angiogenic factors in cancer patients J Clin Oncol 19 1207 25 1:CAS:528:DC%2BD3MXhvFertrc%3D 11181687
23. L Ryden B Linderholm S Emdin P-E Jönsson G Landberg 2003 Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in human breast cancer Breast Cancer Res Treat 82 3 147 54 10.1023/B:BREA.0000004357.92232.cb 1:CAS:528:DC%2BD3sXptVCrur4%3D 14703061 (Pubitemid 37521970)
24. Kato S, Endoh H, Masuhiro Y, Uchiyama S, Sasaki H, Masushige S, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 270:1491-4.
25. AV Lee CN Weng JG Jackson D Yee 1997 Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells J Endocrinol 152 39 47 10.1677/joe.0.1520039 1:CAS:528:DyaK2sXivVKku7s%3D 9014838
26. CK Goldman J Kim WL Wong V King T Brock GY Gillespie 1993 Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology Mol Biol Cell 4 121 33 1:CAS:528:DyaK3sXitFSnsLs%3D 7680247
27. AB Schreiber ME Winkler R Derynck 1986 Transforming growth factor-α: a more potent angiogenic mediator than epidermal growth factor Science (Washington DC) 232 1250 3 10.1126/science.2422759 1:CAS:528: DyaL28XktF2ns74%3D
28. M Dowsett, et al. 2001 HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer Cancer Res 61 23 8452 8 1:CAS:528:DC%2BD3MXptFCktbs%3D 11731427
29. MJ Ellis A Coop B Singh, et al. 2001 Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or Erb-B2-positive, estrogen receptor positive primary breast cancer: evidence from a randomized trial J Clin Oncol 19 3808 16 1:CAS:528:DC%2BD3MXnsVKqsbo%3D 11559718
30. RR Love NB Duc TC Havighurst SK Mohsin Q Zhang D DeMets C Allred 2003 HER-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer J Clin Oncol 21 3 453 7 10.1200/JCO.2003.10.133 1:CAS:528: DC%2BD2cXpsVGrtLw%3D 12560434 (Pubitemid 46606474)
31. BB Rasmussen MM Pegan AE Lykkesfeldt P Dell′Orto B Del Curto KL Henriksen, et al. 2008 Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial Lancet Oncol 9 23 8 10.1016/S1470-2045(07)70386-8 1:CAS:528:DC%2BD1cXivVOmuw%3D%3D 18083065
32. M Dowsett C Allred J Knox E Quinn J Salter C Wale, et al. 2008 Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER2) status with recurrence in the arimidex tamoxifen, alone and in combination trial J Clin Oncol 7 1059 65 10.1200/JCO.2007.12.9437